Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558395 | 0.80 | ABCB1 (0.38) | ABCB1ABCC1NPC1RAB9AS1PR1 | |
| SCHEMBL25856900 | 0.73 | MAOB (0.43) | ABCB1ABCC1NPC1CASP3RAB9A | |
| SCHEMBL25863749 | 0.73 | ABCB1 (0.35) | ABCB1ABCC1S1PR1 | |
| SCHEMBL23558461 | 0.72 | NPC1 (0.45) | ABCB1ABCC1NPC1CASP3RAB9A | |
| SCHEMBL25856856 | 0.70 | NPC1 (0.43) | ABCB1ABCC1NPC1CASP3RAB9A | |
| SCHEMBL25863238 | 0.69 | CXCR1 (0.40) | ABCB1ABCC1NPC1RAB9ACXCR1 | |
| SCHEMBL23558238 | 0.69 | ALDH1A1 (0.45) | NPC1RAB9ACXCR1 | |
| SCHEMBL25856949 | 0.68 | CNR1 (0.41) | ABCB1ABCC1NPC1CASP3RAB9A | |
| SCHEMBL25856895 | 0.67 | RAB9A (0.42) | ABCB1ABCC1NPC1RAB9ACXCR1 | |
| SCHEMBL25856883 | 0.64 | S1PR1 (0.37) | NPC1RAB9ACXCR1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | ABCB1 3052/4885ABCC1 2927/4885NPC1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.